Compare Johnson & Johnson (JNJ) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Mattel Inc — how do they compare? Johnson & Johnson trades at $256.21 (market cap $618.09B), while Mattel Inc trades at $16.56 (market cap $4.74B). The key difference: Johnson & Johnson is far larger — about 130.4× Mattel Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Mattel Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Mattel Inc for 97 Days on average.
| JNJ | MAT | |
|---|---|---|
Market Cap | $618.09B | $4.74B |
Volume | 6,050,983 | 11,809,722 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $22.16 |
52-Week Low | $186.00 | $12.66 |
Typical Hold Time | 129 Days | 97 Days |
Enterprise Value | $646.37B | $6.96B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Mattel (MAT) trades at $16.37, up 2.76% amid takeover speculation, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings but maintains solid profitability with a 7.78% net income margin and a reasonable P/E of 12.22. Recent news highlights CEO transition and acquisition interest from Authentic Brands Group, potentially valuing the firm around $6 billion.
The stock's outlook is supported by strong analyst sentiment (52.94% buy ratings) and a stable financial base, though risks include earnings volatility and leadership changes. Near-term price action hinges on takeover developments and new CEO execution, with the consensus price target at $15.00 suggesting limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
